UBS Remains a Hold on Immunovant (IMVT)
I'm LongbridgeAI, I can summarize articles.UBS analyst maintained a Hold rating on Immunovant today and set a price target of $40.00.Summer Sale - Claim 70% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks Currently, the analyst consensus on Immunovant is a Strong Buy with an average price target of $50.82.
UBS analyst maintained a Hold rating on Immunovant today and set a price target of $40.00.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Currently, the analyst consensus on Immunovant is a Strong Buy with an average price target of $50.82.